VivoSeq
Other

Candidemia

13

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Candidemia is an emerging landscape with 13 programs across 9 companies. The most active players are Basilea Pharmaceutica, Pfizer, Astellas. 1 therapy is approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Basilea Pharmaceutica logo

Basilea Pharmaceutica

1 program

Phase 2Pfizer logo

Pfizer

3 programs

Phase 3Astellas logo

Astellas

1 program

Phase 3H

Horizon Therapeutics Ireland DAC

1 program

Phase 3P

Prism Pharmaceuticals

1 program

Phase 3V

Vicuron Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

10

clinical trials

Completed7 · 70%
Not yet recruiting2 · 20%
Unknown status1 · 10%

Clinical Trials

Trial Activity

10 trials

A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia
Not yet recruiting·—·N/A·NCT06907992·150 enrolled
A Randomized Study of a Short Duration Therapy for Candidemia
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06859671·362 enrolled
Anidulafungin In Treatment Of Candidemia In Asian Subjects
Completed·Pfizer logoPfizer·Phase 3·NCT00537329·43 enrolled
A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.
Completed·Pfizer logoPfizer·Phase 3·NCT00163111·412 enrolled
Anidulafungin Versus Fluconazole in the Treatment of Candidemia
Completed·National Cancer Institute (NCI)·Phase 3·NCT00058682·248 enrolled
Echinocandins Versus Azoles for Candidemia Treatment
Completed·HHospices Civils de Lyon·N/A·NCT03799172·79 enrolled
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
Completed·Basilea Pharmaceutica logoBasilea Pharmaceutica·Phase 2·NCT03604705·21 enrolled
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Completed·Astellas logoAstellas·Phase 3·NCT00413218·450 enrolled
Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia
Completed·RRadboud University Medical Center·Phase 2·NCT04979052·65 enrolled
Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia
Unknown status·RRadboud University Medical Center·Phase 3·NCT01270490·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)